LEVITRA
LOE ApproachingNDAORALTABLET
Approved
Aug 2003
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
7
Data completeness
5/8 — Partial
LEVITRA by Bayer is mechanism of action penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. Approved for erectile dysfunction. First approved in 2003.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEVITRA (vardenafil) is an oral small-molecule PDE5 inhibitor approved in 2003 for erectile dysfunction. It works by inhibiting phosphodiesterase type 5 in the corpus cavernosum, increasing cGMP levels and enhancing smooth muscle relaxation to enable penile blood flow during sexual stimulation.
LOE Approaching1.1 years to LOE
Product is 1.1 years from LOE with 15 known competitors; brand teams face significant portfolio pressure and likely workforce optimization.
Mechanism of Action
Mechanism of Action Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide…
Indications (1)
Worked on LEVITRA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.